中国批准葛兰素史克的Teggy Ellipta用于成人哮喘治疗

2026-01-23 18:51

GSK (GSK) said on Friday that China’s National Medical Products Administration approved a new indication for Trelegy Ellipta to treat adults with asthma, expanding its approved use beyond chronic obstructive pulmonary disease.
The approval means that FF/UMEC/VI is the first and only single-inhaler triple therapy approved for the maintenance treatment of both respiratory conditions in the country.
Approval was based on GSK’s CAPTAIN study, which showed that in patients uncontrolled on inhaled corticosteroids/long-acting beta agonist (ICS/LABA), the additional bronchodilation provided by FF/UMEC/VI demonstrated significant improvements in lung function compared with FF/VI.
Source: Press release

More on GSK